Mylan warns of possible drug shortages, financial hit due to coronavirus Medical Dialogues Bureau29 Feb 2020 9:30 AM ISTAlthough heavily reliant on China, the company said it was better positioned against the impact of the outbreak compared to its peers due to its...
Mylan to infuse USD 1 billion on capex in India Medical Dialogues Bureau30 Sept 2019 9:30 AM ISTMylan Global President and Executive Director Rajiv Malik said the company had been investing close to about USD 400 million or USD 450 million...
Mylan launches generic version of Faslodex Injection to treat breast cancer Medical Dialogues Bureau19 Sept 2019 9:35 AM ISTNew Delhi: Mylan N.V. recently announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic...
USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta Ruby Khatun Khatun6 Jun 2018 10:30 AM ISTHERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 10:00 AM ISTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Biocon, Mylan Present Clinical Data on Insulin Glargine at American Diabetes Associations 77th Scientific Sessions Ruby Khatun Khatun12 Jun 2017 11:29 AM ISTMylan N.V. and Biocon Ltd. announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the...
